ORIC Pharmaceuticals Inc ORIC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
-
ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates
-
ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs
-
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer
-
Attovia Therapeutics Announces Election of Mitchell Gold and Angie You to Board of Directors
Trading Information
- Previous Close Price
- $9.54
- Day Range
- $9.43–9.80
- 52-Week Range
- $5.27–16.65
- Bid/Ask
- $3.85 / $9.85
- Market Cap
- $677.91 Mil
- Volume/Avg
- 202,037 / 521,568
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 107
- Website
- https://www.oricpharma.com
Comparables
Valuation
|
Metric
|
ORIC
|
BDTX
|
ACLX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.15 | 1.91 | 8.61 |
Price/Sales | — | — | 27.51 |
Price/Cash Flow | — | — | 507.02 |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ORIC
|
BDTX
|
ACLX
|
|---|---|---|---|
Quick Ratio | 14.66 | 6.67 | 5.85 |
Current Ratio | 15.08 | 6.87 | 6.01 |
Interest Coverage | — | — | −28.35 |
Quick Ratio
ORIC
BDTX
ACLX
Profitability
|
Metric
|
ORIC
|
BDTX
|
ACLX
|
|---|---|---|---|
Return on Assets (Normalized) | −31.05% | −46.40% | −1.88% |
Return on Equity (Normalized) | −33.92% | −62.87% | −3.31% |
Return on Invested Capital (Normalized) | −33.58% | −52.48% | −7.10% |
Return on Assets
ORIC
BDTX
ACLX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Dsmzznjg | Nyrz | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Qkhgklwv | Xhxgbx | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Dvczfnjk | Srzkfj | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Xcbxxqtyg | Cyfvjp | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Shjjtkcg | Nwpk | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Mbtbxmqn | Jyk | $29.2 Bil | |||
| Moderna Inc
MRNA
| Wjhrtnfy | Wjhj | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Shpnxlqm | Fpm | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Rjcfsvp | Vgbsfp | $13.2 Bil | |||
| Incyte Corp
INCY
| Khxdfvtrf | Jhnztf | $13.0 Bil |
United States